Affiliation: Cornell University
Murray H, Mitchell Flack M, Taylor G, Ma X. IFN-Î³-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver. Exp Parasitol. 2015;157:103-9 pubmed publisher
..donovani infection in the liver, the absence of either Irgm1 or Irgm3 impairs early inflammation and initial resistance; the absence of Irgm3, but not Irgm1, also appears to impair the intracellular efficacy of Sb chemotherapy. ..
Murray H, Mitchell Flack M, Zheng H, Ma X. Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection. Infect Immun. 2015;83:702-12 pubmed publisher
..These results, in susceptible B6 mice for GzmB and in resistant 129/Sv mice for GzmA and/or the GzmB cluster, point to granzyme-mediated host defense regulation in the liver in experimental visceral leishmaniasis. ..
Murray H, Luster A, Zheng H, Ma X. Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver. Infect Immun. 2017;85: pubmed publisher
Murray H, Tsai C, Liu J, Ma X. Visceral Leishmania donovani infection in interleukin-13-/- mice. Infect Immun. 2006;74:2487-90 pubmed
..By itself, interleukin-13 does not appear to materially influence acquired resistance in this intracellular infection. ..
Murray H, Montelibano C, Peterson R, Sypek J. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis. 2000;182:1497-502 pubmed
..Thus, IL-12 regulates host IFN-gamma-dependent and -independent responses that permit and/or enhance the leishmanicidal activity of Sb. ..
Murray H, Lu C, Brooks E, Fichtl R, DeVecchio J, Heinzel F. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun. 2003;71:6453-62 pubmed
Murray H, Xiang Z, Ma X. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase. Am J Trop Med Hyg. 2006;74:1013-5 pubmed
..Nevertheless, visceral infection was controlled post-treatment and did not recur. A phox/iNOS-independent macrophage mechanism, which was not triggered by L. donovani, emerges after chemotherapy. ..
Murray H, Tsai C, Liu J, Ma X. Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect Immun. 2006;74:4370-4 pubmed
..Nevertheless, testing in IL-18(-/-) mice compared to wild-type mice and in IL-12p40(-/-) compared to IL-12p35(-/-) mice also suggested both early-acting (IL-18) and late-acting (IL-23) antileishmanial effects independent of IL-12. ..
Murray H. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice. Infect Immun. 2008;76:4088-91 pubmed publisher
..In this model of visceral leishmaniasis, IL-6 appears to act in a suppressive, macrophage-deactivating fashion, which identifies it as a potential target for therapeutic blockade. ..